Last Updated: November 16, 2026

OLINVYK Drug Patent Profile

« Back to Dashboard


When do Olinvyk patents expire, and what generic alternatives are available?

Olinvyk is a drug marketed by Trevena and is included in one NDA. There are five patents protecting this drug.

The generic ingredient in OLINVYK is oliceridine. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the oliceridine profile page.

DrugPatentWatch® Generic Entry Outlook for Olinvyk

Olinvyk was eligible for patent challenges on October 30, 2024.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be March 23, 2032. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

< Available with Subscription >

  Start Trial

AI Deep Research
Questions you can ask:
  • What is the 5 year forecast for OLINVYK?
  • What are the global sales for OLINVYK?
  • What is Average Wholesale Price for OLINVYK?
Summary for OLINVYK
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for OLINVYK
Generic Entry Date for OLINVYK*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:

SOLUTION;INTRAVENOUS

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

US Patents and Regulatory Information for OLINVYK

OLINVYK is protected by five US patents.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of OLINVYK is ⤷  Start Trial.

This potential generic entry date is based on patent ⤷  Start Trial.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Trevena OLINVYK oliceridine SOLUTION;INTRAVENOUS 210730-001 Oct 30, 2020 DISCN Yes No ⤷  Start Trial ⤷  Start Trial Y ⤷  Start Trial
Trevena OLINVYK oliceridine SOLUTION;INTRAVENOUS 210730-002 Oct 30, 2020 DISCN Yes No ⤷  Start Trial ⤷  Start Trial Y ⤷  Start Trial
Trevena OLINVYK oliceridine SOLUTION;INTRAVENOUS 210730-001 Oct 30, 2020 DISCN Yes No ⤷  Start Trial ⤷  Start Trial Y Y ⤷  Start Trial
Trevena OLINVYK oliceridine SOLUTION;INTRAVENOUS 210730-003 Oct 30, 2020 DISCN Yes No ⤷  Start Trial ⤷  Start Trial Y ⤷  Start Trial
Trevena OLINVYK oliceridine SOLUTION;INTRAVENOUS 210730-002 Oct 30, 2020 DISCN Yes No ⤷  Start Trial ⤷  Start Trial Y Y ⤷  Start Trial
Trevena OLINVYK oliceridine SOLUTION;INTRAVENOUS 210730-003 Oct 30, 2020 DISCN Yes No ⤷  Start Trial ⤷  Start Trial Y Y ⤷  Start Trial
Trevena OLINVYK oliceridine SOLUTION;INTRAVENOUS 210730-001 Oct 30, 2020 DISCN Yes No ⤷  Start Trial ⤷  Start Trial Y ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for OLINVYK

When does loss-of-exclusivity occur for OLINVYK?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Patent: 12230761
Patent: Opioid receptor ligands and methods of using and making same
Estimated Expiration: ⤷  Start Trial

Patent: 17200745
Patent: Opioid receptor ligands and methods of using and making same
Estimated Expiration: ⤷  Start Trial

Brazil

Patent: 2013024136
Patent: ligandos de receptor de opióide e métodos de usar e fabricar os mesmos
Estimated Expiration: ⤷  Start Trial

Canada

Patent: 30742
Patent: OXANES SUBSTITUES COMME LIGANDS DE RECEPTEUR OPIOIDE ET METHODES D'UTILISATION ET DE FABRICATION ASSOCIEES (SUBSTITUTED OXANES AS OPIOID RECEPTOR LIGANDS AND METHODS OF USING AND MAKING SAME)
Estimated Expiration: ⤷  Start Trial

China

Patent: 3702561
Patent: Opioid receptor ligands and methods of using and making same
Estimated Expiration: ⤷  Start Trial

Croatia

Patent: 0171021
Estimated Expiration: ⤷  Start Trial

Cyprus

Patent: 19057
Estimated Expiration: ⤷  Start Trial

Denmark

Patent: 88403
Estimated Expiration: ⤷  Start Trial

Patent: 90415
Estimated Expiration: ⤷  Start Trial

Eurasian Patent Organization

Patent: 5456
Patent: ЛИГАНДЫ ОПИОИДНЫХ РЕЦЕПТОРОВ И СПОСОБЫ ИХ ПРИМЕНЕНИЯ И ПОЛУЧЕНИЯ (OPIOID RECEPTOR LIGANDS AND METHODS OF USING AND MAKING SAME)
Estimated Expiration: ⤷  Start Trial

Patent: 1391332
Patent: ЛИГАНДЫ ОПИОИДНЫХ РЕЦЕПТОРОВ И СПОСОБЫ ИХ ПРИМЕНЕНИЯ И ПОЛУЧЕНИЯ (OPIOID RECEPTOR LIGANDS AND METHODS OF USING AND MAKING SAME)
Estimated Expiration: ⤷  Start Trial

European Patent Office

Patent: 88403
Patent: LIGANDS DE RÉCEPTEURS OPÏOIDES, ET LEURS PROCÉDÉS D'UTILISATION ET DE PRODUCTION (OPIOID RECEPTOR LIGANDS AND METHODS OF USING AND MAKING SAME)
Estimated Expiration: ⤷  Start Trial

Patent: 90415
Patent: LIGANDS DE RÉCEPTEURS OPÏOIDES, ET LEURS PROCÉDÉS D'UTILISATION ET DE PRODUCTION (OPIOID RECEPTOR LIGANDS AND METHODS OF USING AND MAKING SAME)
Estimated Expiration: ⤷  Start Trial

Patent: 72076
Patent: LIGANDS DE RÉCEPTEURS OPÏOIDES, ET LEURS PROCÉDÉS D'UTILISATION ET DE PRODUCTION (OPIOID RECEPTOR LIGANDS AND METHODS OF USING AND MAKING SAME)
Estimated Expiration: ⤷  Start Trial

Hong Kong

Patent: 50984
Patent: 阿片樣物質受體配體以及使用和製備其的方法 (OPIOID RECEPTOR LIGANDS AND METHODS OF USING AND MAKING SAME)
Estimated Expiration: ⤷  Start Trial

Hungary

Patent: 32948
Estimated Expiration: ⤷  Start Trial

Patent: 54055
Estimated Expiration: ⤷  Start Trial

Israel

Patent: 8506
Patent: ליגנדים של קולטן אופיואיד ותכשירי רוקחות המכילים אותם (Opioid receptor ligands and pharmaceutical compositions comprising them)
Estimated Expiration: ⤷  Start Trial

Patent: 3318
Patent: ליגנדים של קולטן אופיואיד ושיטות לשימוש בהם ולהכנתם (Opioid receptor ligands and methods of using and making same)
Estimated Expiration: ⤷  Start Trial

Patent: 2165
Patent: ליגנדים של קולטן אופיואיד ושיטות לשימוש בהם ולהכנתם (Opioid receptor ligands and methods of using and making same)
Estimated Expiration: ⤷  Start Trial

Patent: 4407
Patent: ליגנדים של קולטן אופיואיד ושיטות לשימוש בהם ולהכנתם (Opioid receptor ligands and methods of using and making same)
Estimated Expiration: ⤷  Start Trial

Japan

Patent: 12169
Estimated Expiration: ⤷  Start Trial

Patent: 43949
Estimated Expiration: ⤷  Start Trial

Patent: 49341
Estimated Expiration: ⤷  Start Trial

Patent: 23683
Estimated Expiration: ⤷  Start Trial

Patent: 48750
Estimated Expiration: ⤷  Start Trial

Patent: 14508811
Patent: オピオイド受容体リガンド並びにそれらの使用方法及び製造方法
Estimated Expiration: ⤷  Start Trial

Patent: 16155843
Patent: オピオイド受容体リガンド並びにそれらの使用方法及び製造方法 (OPIOID RECEPTOR LIGANDS AND METHODS OF USING AND MAKING THE SAME)
Estimated Expiration: ⤷  Start Trial

Patent: 18048193
Patent: オピオイド受容体リガンド並びにそれらの使用方法及び製造方法 (OPIOID RECEPTOR LIGANDS AND METHODS OF USING AND MAKING THE SAME)
Estimated Expiration: ⤷  Start Trial

Patent: 20073570
Patent: オピオイド受容体リガンド並びにそれらの使用方法及び製造方法 (OPIOID RECEPTOR LIGANDS AND METHODS OF USING AND MAKING THE SAME)
Estimated Expiration: ⤷  Start Trial

Patent: 21176885
Patent: オピオイド受容体リガンド並びにそれらの使用方法及び製造方法 (OPIOID RECEPTOR LIGAND AND METHODS OF USING AND MAKING THE SAME)
Estimated Expiration: ⤷  Start Trial

Patent: 23075282
Patent: オピオイド受容体リガンド並びにそれらの使用方法及び製造方法
Estimated Expiration: ⤷  Start Trial

Lithuania

Patent: 88403
Estimated Expiration: ⤷  Start Trial

Montenegro

Patent: 754
Patent: LIGANDI OPIOIDNIH RECEPTORA I POSTUPCI NJIHOVE UPOTREBE I PRIPREME (OPIOID RECEPTOR LIGANDS AND METHODS OF USING AND MAKING SAME)
Estimated Expiration: ⤷  Start Trial

New Zealand

Patent: 5993
Patent: Opioid receptor ligands and methods of using and making same
Estimated Expiration: ⤷  Start Trial

Patent: 3143
Patent: Opioid receptor ligands and methods of using and making same
Estimated Expiration: ⤷  Start Trial

Poland

Patent: 88403
Estimated Expiration: ⤷  Start Trial

Patent: 90415
Estimated Expiration: ⤷  Start Trial

Portugal

Patent: 88403
Estimated Expiration: ⤷  Start Trial

Patent: 90415
Estimated Expiration: ⤷  Start Trial

San Marino

Patent: 01700325
Estimated Expiration: ⤷  Start Trial

Serbia

Patent: 111
Patent: LIGANDI OPIOIDNIH RECEPTORA I POSTUPCI NJIHOVE UPOTREBE I PRIPREME (OPIOID RECEPTOR LIGANDS AND METHODS OF USING AND MAKING SAME)
Estimated Expiration: ⤷  Start Trial

Slovenia

Patent: 88403
Estimated Expiration: ⤷  Start Trial

South Korea

Patent: 1991326
Estimated Expiration: ⤷  Start Trial

Patent: 1991327
Estimated Expiration: ⤷  Start Trial

Patent: 2129247
Estimated Expiration: ⤷  Start Trial

Patent: 140047599
Patent: 오피오이드 수용체 리간드와 그 용도 및 제조방법 (Opioid Receptor Ligands and Methods of Using and Making Same)
Estimated Expiration: ⤷  Start Trial

Patent: 180100453
Patent: 오피오이드 수용체 리간드와 그 용도 및 제조방법 (Opioid Receptor Ligands and Methods of Using and Making Same)
Estimated Expiration: ⤷  Start Trial

Patent: 190072665
Patent: 오피오이드 수용체 리간드와 그 용도 및 제조방법 (Opioid Receptor Ligands and Methods of Using and Making Same)
Estimated Expiration: ⤷  Start Trial

Spain

Patent: 32009
Estimated Expiration: ⤷  Start Trial

Patent: 57549
Estimated Expiration: ⤷  Start Trial

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering OLINVYK around the world.

Country Patent Number Title Estimated Expiration
Australia 2012230761 ⤷  Start Trial
Australia 2017200745 ⤷  Start Trial
Brazil 112013024136 ⤷  Start Trial
Canada 2830742 ⤷  Start Trial
China 103702561 ⤷  Start Trial
Cyprus 1119057 ⤷  Start Trial
Denmark 2688403 ⤷  Start Trial
>Country >Patent Number >Title >Estimated Expiration

OLINVYK market dynamics and financial trajectory (revenue outlook, exclusivity tailwinds, and competitive pressure)

Last updated: July 25, 2026

Executive summary

  • OLINVYK revenue trajectory is driven by (1) OLINVYK’s launch and uptake rate by treated patient pools, (2) payer coverage for its indication(s), (3) durability of exclusivity protection versus near-term generic/biosimilar or competitive substitution, and (4) sensitivity to gross-to-net via rebates, copays, and channel mix.
  • The practical market inflection points are tied to label expansion, formulary wins, and the timing of any Orange Book-listed patent challenges or exclusivity expirations that would enable generic entry (if applicable).
  • A complete, decision-grade view requires OLINVYK’s exact active ingredient, dosage forms, FDA approval date(s), FDA label indications, Orange Book listings, and the current competitive set. Without those identifiers and the associated FDA and patent records, a defensible financial trajectory and market-dynamics forecast cannot be produced.

What is OLINVYK’s market size exposure by indication and patient pool?

OLINVYK’s revenue ceiling is determined by the addressable patient population for each labeled indication, then constrained by the share of eligible patients that converts into filled prescriptions.

Key revenue drivers (indication-level)

  • Eligible prevalence: diagnosed population × eligibility for the labeled regimen.
  • Treatment switch rate: penetration among patients currently treated with competing standards of care.
  • Persistence: proportion staying on therapy long enough to sustain annualized dosing.
  • Dosing and regimen intensity: units per patient-year and variability by patient subgroup.

Key constraints (payer and reimbursement)

  • Coverage depth: restriction to preferred tiers, prior authorization criteria, and step edits.
  • Net price: rebate structure, ASP-to-WAC spread, wholesaler fees, and patient assistance impact.
  • Site of care: if administration setting affects buy-and-bill dynamics versus specialty pharmacy flows.

How does OLINVYK’s exclusivity structure shape revenue durability?

Revenue durability depends on patent term and any regulatory exclusivities that extend barrier to entry.

Exclusivity levers to map for OLINVYK

  • Patent estate breadth: composition of matter, method of treatment, and formulation/process claims.
  • FDA exclusivities (if applicable): new chemical entity (NCE), new therapeutic biologic entity (NTB), orphan drug (if designated), pediatric exclusivity, and exclusivity extensions tied to pediatric studies.
  • “Skinny labeling” risk: for small-molecule drugs, which claims remain enforceable after generic design-around.

Revenue impact

  • Longer exclusivity tail typically increases lifetime prescribing stability, allowing the manufacturer to broaden payers and strengthen net retention.
  • Narrow estates or weak method-of-use coverage increases incentives for challengers and accelerates erosion once an at-risk launch appears.

What patents protect OLINVYK and how strong is the patent estate?

A litigation-grade patent strength assessment requires the enumerated Orange Book listings (and relevant patents not listed in Orange Book) and their remaining life by claim type.

Patent estate map needed for OLINVYK

  • Composition of matter patents: earliest barriers to a generic.
  • Method-of-use patents: often the fulcrum for “use carve-out” labels.
  • Formulation and delivery patents: typically affect bioequivalence design space and manufacturing.
  • Process patents: can increase manufacturing IP friction even if composition is challenged.

How to assess “strength” operationally

  • Claim coverage breadth: scope of active ingredient, salts/polymorphs, and dosage forms.
  • Expiry stagger: whether exclusivity is concentrated or layered.
  • Litigation history: prior enforcement outcomes in the same claim family.
  • Enabling disclosures: whether generic design-arounds are realistically feasible without infringing.

When does OLINVYK lose exclusivity and when do generics enter?

The exclusivity timeline sets the highest-impact market event schedule: at-risk entry, settlement-driven launch dates, and expected prescription migration speed.

Timeline inputs required for OLINVYK

  • FDA approval date for the first marketing authorization of the active ingredient.
  • Orange Book patent expiry dates (each listed patent’s expiration and any terminal disclaimers).
  • Any PTE (patent term adjustment) events and pediatric exclusivity additions.
  • Any known Paragraph IV notice windows and the resulting triggered 180-day exclusivity (if a first filer).

Market translation

  • Near-term generic threat compresses prescriber behavior and increases payer leverage.
  • Settlement dates can produce a “cliff” in competitive pressure, with follow-on impacts on rebate intensity.

What is the Orange Book status of OLINVYK and what does it imply for launch risk?

Orange Book status typically indicates whether the drug is exposed to standard generic substitution pathways (ANDA with bioequivalence) or, for biologics, biosimilar pathways.

Decision points

  • Whether OLINVYK has listed patents and how many are listed.
  • Whether those patents include method-of-use claims that can be carved out.
  • Whether there are “multiple expiration buckets,” which changes generic timing.

Generic/biosimilar risk model

  • High risk: minimal enforceable composition claims remaining, no strong method-of-use coverage, and short remaining patent life.
  • Medium risk: enforceable method-of-use claims block immediate switching; generic entry only after label carve-outs.
  • Low risk: layered composition + formulation + method-of-use coverage with long remaining life.

Which companies are challenging OLINVYK via Paragraph IV and what is the litigation calendar?

Paragraph IV challenges determine whether generic entry occurs “at risk” before final adjudication and whether the brand is protected through settlement.

Litigation-driven market effects

  • A pending case can increase uncertainty but also prompt earlier payer contracting changes.
  • Settlements can lock in “first generic” dates and prevent further at-risk filings.

Calendar elements required for a full answer

  • Notice of Paragraph IV filing date(s).
  • Parties: NDA holder and each challenger.
  • Court and jurisdiction: District of Delaware and related appellate path.
  • Case status: dismissed, stayed, summary judgment, trial outcome.
  • Settlement: final agreement date and permissible launch date window.

How does OLINVYK compare with competing drugs on efficacy, administration, and payer preference?

Competitive dynamics in branded pharma are determined by clinical differentiation and how easily payers can manage utilization.

Comparison dimensions that change market share

  • Efficacy metrics used in reimbursement: endpoints in pivotal trials and subgroup data relevant to payer criteria.
  • Safety and monitoring burden: adverse event profile and lab frequency.
  • Dosing frequency and administration: oral versus injectable, infusion time, storage, and clinician workload.
  • Co-medication requirements: concomitant therapies that raise total treatment cost.

Payer preference mechanics

  • Preferred tier positioning depends on net cost, prior authorization criteria, and formulary value frameworks.
  • PBM design can accelerate uptake if OLINVYK is placed on lower-cost tiers.

What formulations are protected by OLINVYK patents and how does that affect substitution risk?

Formulation patents can block certain generic designs even if composition claims are attacked.

Formulation-patent friction points

  • Salt form and polymorph coverage
  • Release profile and excipient systems
  • Device and delivery (if applicable)
  • Stability and manufacturing-process constraints

Net effect

  • If formulation protection survives longer than composition, market erosion can be delayed or limited to partial substitution.

What manufacturing and IP barriers could slow generic entry for OLINVYK?

Even when patents are weak or nearing expiry, manufacturing readiness can determine launch speed.

Typical barriers

  • Process know-how not disclosed in sufficient detail for ANDA scale-up.
  • Controlled release performance requirements.
  • Raw material sourcing constraints for the same grade/spec.
  • Device or combination product dependencies (if relevant).

Market outcome

  • Slower generic supply yields slower price erosion and maintains higher gross-to-net for longer.

What FDA regulatory pathway and label scope govern OLINVYK’s competitive exposure?

Regulatory scope determines both the eligible switching population and the design constraints for challengers.

Key pathway variables

  • Full approval versus accelerated approval (if applicable).
  • Single-dose versus chronic dosing labeling.
  • Indication-by-indication exclusivity and label expansion sequencing.

Label scope and substitution

  • Broader label = more switching opportunities for a generic entrant.
  • Narrow or restricted label = more prior authorization leverage for the brand.

What is the revenue model for OLINVYK: pricing, gross-to-net, and channel mix?

A credible financial trajectory uses unit sales, ASP-based pricing, and gross-to-net drivers.

Revenue mechanics to model

  • Units: scripts or vials, then conversion into patient-days or patient-years.
  • Price: list price and net price after rebates and discounts.
  • Mix: specialty pharmacy versus buy-and-bill, and geography.
  • Timing: inventory builds and seasonal demand patterns.

Gross-to-net drivers

  • Rebates: volume-based and formulary-based.
  • Copay assistance: offsets patient cost share, but increases brand “net” cost exposure.
  • Chargebacks and administration fees: channel-specific components.

What is OLINVYK’s financial trajectory based on launch uptake and payer penetration?

Without OLINVYK’s FDA approval date, labeled indications, current prescription volume, and comparable brand performance metrics, a quantitative revenue projection cannot be made.

The only actionable framework

  • If OLINVYK is in early lifecycle, revenue follows a near-term curve driven by payer access and prescriber conversion.
  • Mid lifecycle typically shows flattening unless label expands or competitive intensity increases.
  • Late lifecycle shows net-to-price compression ahead of generic/biosimilar entry.

What to measure (and why it matters)

  • Script growth versus discontinuation or substitution rates.
  • Payer coverage breadth and formulary tier movement.
  • Net revenue per unit trends and gross-to-net trend stability.

How much of OLINVYK revenue is at risk from generics or biosimilars?

Revenue at risk is a function of (1) remaining exclusivity and (2) how replaceable the product is clinically and administratively.

Risk segmentation

  • At-risk switchable indications: parts of the label exposed to generic substitution.
  • Non-switchable segments: restricted subpopulations with limited coverage.
  • Institutional barriers: administration workflows that slow substitution.

Scenario structure

  • Low-risk: long patent tail and strong formulary placement.
  • Medium-risk: method-of-use barriers but possible design-around.
  • High-risk: composition and formulation coverage expiring or already vulnerable with a clear competitor plan.

Key takeaways

  • OLINVYK’s market dynamics are determined by exclusivity durability, Orange Book enforceability, payer coverage depth, and net price retention.
  • The highest-value decision inputs for revenue and competitive risk are the FDA label scope, approval timeline, Orange Book patent list with remaining life, and any Paragraph IV litigation or settlements.
  • A defensible financial trajectory requires those identifiers; without them, any quantified revenue outlook would be non-actionable.

FAQs

  1. How do Orange Book patent listings for OLINVYK affect generic launch timing?
  2. What Paragraph IV settlement terms typically control OLINVYK brand revenue erosion?
  3. How do payer prior authorization rules change OLINVYK net sales versus list price?
  4. Which formulation or method-of-use patents usually block “skinny label” competition for drugs like OLINVYK?
  5. What indicators in FDA filings predict competitive substitution risk for OLINVYK (ANDA/BLA trends)?

References

  1. FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration. (Accessed 2026-07-25).
  2. FDA. Paragraph IV: ANDA Litigation and 180-Day Exclusivity Overview (public guidance and related resources). U.S. Food and Drug Administration. (Accessed 2026-07-25).

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.